Tacrolimus is characterized by a highly variable pharmacokinetics (PK) and a small
therapeutic window. It is metabolized specifically by the CYP3A isoenzymes. This study …

OBJECTIVES: Tacrolimus is a widely used immunosuppressive drug in organ
transplantation. The oral bioavailability of tacrolimus varies greatly between individuals and …

Aim: The influence of variants in pharmacokinetics-related genes on long-term exposure to
tacrolimus (TAC)-based therapy and clinical outcomes was investigated. Patients & …

INTRODUCTION AND AIMS: Despite Tacrolimus (TAC) dosing is routinely directed by
Therapeutic Drug Monitoring (TDM), some patients reach the concentrations target (CT) …

Aim: To analyze the influence of CYP3A5 polymorphisms on TAC pharmacokinetics and
renal function in adult renal transplant patients at 1 and 12 month post-transplant. Patients …

Conclusions: The polymorphisms of the human multidrug resistance gene MDR1 (C3435T,
C1236T and G2677T) were influenced by Pgp function in vivo in lymphocytes isolated from …

Tacrolimus is an immunosuppressive drug widely used in kidney transplantation.
Cytochrome P450 3A5 (CYP3A5) protein is involved in tacrolimus metabolism. Single …

Background Previous reports have established that patient CYP3A5 allelic variability may be
the most important genetic contributor to interindividual variation in tacrolimus exposure in …

Background. Tacrolimus, a calcineurin inhibitor, is prescribed to prevent allograft rejection in
renal transplantation. Tacrolimus not only has a narrow therapeutic index, but also shows …

Background: Our study aimed to investigate the pharmacogenetics of cytochrome P3A4
(CYP3A4), CYP3A5, CYP2C8, and CYP2C19 and their influence on TAC Pharmacokinetics …